Halozyme Therapeutics (United States)

Halozyme Therapeutics is a biotechnology company developing enzyme-based drug delivery technologies. The company’s ENHANZE platform using recombinant human hyaluronidase (rHuPH20) enables subcutaneous delivery of biologics and other drugs that previously required IV administration. Halozyme partners with major pharmaceutical companies to create patient-friendly subcutaneous formulations of important medications including immunotherapies and monoclonal antibodies.